DUBLIN--(BUSINESS WIRE)--The "Hemodialysis Catheters Pipeline Insight and Competitive Landscape, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
The "Hemodialysis Catheters - Pipeline Insight and Competitive Landscape, 2020," report provides comprehensive insights about 15+ companies and 15+ pipeline devices in Hemodialysis Catheters pipeline landscape.
The global dialysis population is increasing rapidly, particularly in low-income and middle-income countries; however, a significant number of people globally lack access to renal replacement therapy, and millions of people die each year from kidney failure, mostly without supportive care. The expense of dialysis care is high, and is likely to continue to increase as a result of higher life expectancy and enhanced therapies for renal failure causes such as diabetes mellitus and cardiovascular disease.
Patients, payers, regulators and health-care systems are demanding higher competitive advantages in dialysis care, which can only be achieved through genuine patient-centered innovation that continues to support high-quality, high-value care which will lead to increase in market growth.
Hemodialysis Catheters Competitive Assessment
This segment of the Hemodialysis Catheters report encloses its detailed analysis of various pipeline devices which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates and the latest news and press releases. The report also provides list of major players involved in the pipeline product development.
Major Players in Hemodialysis Catheters
There are approx. 15+ key companies which are developing the products for Hemodialysis Catheters.
SureFlow: Ash Access Technology Inc
The Ash SureFlow is an innovative long-term (>30 days) tunneled central venous catheter for hemodialysis. It is under clinical testing and has following features:
- Catheter lumen tips that actively open to promote flow, clear sheathing and thrombus.
- Catheter lumen tips that actively close to retain injected catheter therapies that potentially assist in the prevention of flow failures, catheter-related infections or the development of biofilm.
- Patient and caregiver friendly "catheter hub" that can be actuated before and after dialysis sessions.
- Deformable catheter lumen tips that will assist in keeping the appropriate distance between the vein wall and the catheter and ultimately reduce recirculation
Dialysis catheter: Access Vascular
Access Vascular is developing a comprehensive suite of venous access devices, including peripheral venous catheters, dialysis catheter and ports.
Hemodialysis Catheters Competitive Benchmarking
This segment of the reports provides analysis of the pipeline report to give a clear understanding of the comparative analysis.
The analysis is based on
- Brand Positioning of Leading companies
- Application
- Industry Collaborations
Hemodialysis Catheters: Commercialization Activity
This segment of the report provides a detailed list of any commercial activity in the field of hemodialysis catheters ranging from collaboration, mergers and acquisition, recent breakthrough among others.
Development Activities
- May 2020, Study findings indicated that although most patients who had insurance before developing end-stage renal disease initiate hemodialysis with a central venous catheter, use of fistula for vascular access demonstrated the lowest risk for subsequent bloodstream infections. The researchers contended that the initiation of hemodialysis with a fistula has repeatedly been shown to lead to better outcomes than initiation with a central venous catheter (CVC), the latter of which has been linked to septicemia and high mortality rates.
- A recently published review, "Preventing Bloodstream infections in Hemodialysis Patients" by Michele H. Mokrzycki, in the March 2020 issue states that, the costs of dialysis care are high and will likely continue to rise as a result of increased life expectancy and improved therapies for causes of kidney failure such as diabetes mellitus and cardiovascular disease.
Hemodialysis Catheters: Reimbursement
Reimbursement for peritoneal dialysis is lower in most countries except Germany and the United States. The United Kingdom is the only country that has implemented an incentive if patients use an arteriovenous fistula. A factor of 3.3 for self-care hemodialysis, a factor of 3.2 for home hemodialysis, a factor of 2.5 for hospital hemodialysis, a factor of 2.2 for continuous ambulatory peritoneal dialysis (CAPD), and a factor of 1.8 for automated peritoneal dialysis (APD). In general, the United States and Ontario provide the lowest reimbursement, with the exception of reimbursement for CAPD; the reimbursement for CAPD is the lowest in the United Kingdom.
Key Questions
- What are significant companies in this segment, their information, analysis, and insights to improve R&D strategies?
- How to identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage?
- What are important and diverse types of Hemodialysis Catheters under development?
- What are market-entry and market expansion strategies in Hemodialysis Catheters?
- What are some of the mergers and acquisitions and to identify major players with the most promising pipeline?
- What is in-depth analysis of the product's current stage of development, territory and estimated launch date?
Key Players
- Access Vascular Inc
- Angiotech Pharmaceuticals Inc
- Ariste Medical LLC
- Ash Access Technology Inc
- Chrysalis Medical Inc
- Marvao Medical Devices Ltd
- Phase One Medical LLC
- Silmag SA
- TVA Medical
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/uapeul
